ProtoKinetix, Inc. (OTCMKTS:PKTX) CEO Clarence Edward Smith bought 252,030 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The shares were bought at an average price of $0.12 per share, for a total transaction of $30,243.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Clarence Edward Smith also recently made the following trade(s):
- On Tuesday, June 4th, Clarence Edward Smith bought 142,252 shares of ProtoKinetix stock. The shares were bought at an average price of $0.15 per share, for a total transaction of $21,337.80.
PKTX opened at $0.20 on Thursday. ProtoKinetix, Inc. has a 52-week low of $0.05 and a 52-week high of $0.32. The business’s 50-day simple moving average is $0.23 and its 200 day simple moving average is $0.14.
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in food and crop preservation at freezing temperatures.
Read More: What is a death cross?
Receive News & Ratings for ProtoKinetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProtoKinetix and related companies with MarketBeat.com's FREE daily email newsletter.